Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 5/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491824 | 0.86 | HTR4 (0.47) | SIGMAR1HTR4DRD4DRD2ACHE | |
| SCHEMBL11900225 | 0.84 | ALDH1A1 (0.41) | HTR4CYP3A4ADRA2CHTR2BHTR3A | |
| SCHEMBL11901919 | 0.82 | ALDH1A1 (0.48) | SIGMAR1ACHECYP1A2CYP2D6MEN1 | |
| SCHEMBL15600809 | 0.79 | ALDH1A1 (0.44) | HTR4CYP3A4ADRA2CHTR2BHTR3A | |
| SCHEMBL10259180 | 0.78 | SIGMAR1 (0.50) | SIGMAR1DRD4ACHEKMT2AALDH1A1 | |
| SCHEMBL30184542 | 0.76 | ALDH1A1 (0.49) | CYP3A4ADRA2BMEN1KMT2AALDH1A1 | |
| SCHEMBL894392 | 0.76 | SIGMAR1 (0.59) | SIGMAR1DRD4ACHECYP3A4KMT2A | |
| SCHEMBL22232917 | 0.75 | ALDH1A1 (0.40) | HTR4CYP3A4ADRA2CADRA1AHTR2B | |
| SCHEMBL11916218 | 0.75 | ALDH1A1 (0.47) | HTR4CYP3A4ADRA2BMEN1KMT2A | |
| SCHEMBL13619289 | 0.74 | ALDH1A1 (0.46) | HTR4CYP3A4ADRA2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| EP-2300013-B1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMA INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | ARIAD PHARMA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-2300013-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD Pharmaceuticals, Inc (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009143389-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | SIGMAR1 3464/4885HTR4 4666/4885DRD4 4797/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | SIGMAR1 3576/4885HTR4 4784/4885DRD4 4868/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | SIGMAR1 3112/4885HTR4 4686/4885DRD4 4846/4885 |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | MAP3K6, PIK3CA, MAP3K20 | SIGMAR1 3899/4885HTR4 4750/4885DRD4 4866/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | SIGMAR1 3576/4885HTR4 4784/4885DRD4 4868/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | SIGMAR1 3464/4885HTR4 4666/4885DRD4 4797/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | SIGMAR1 3464/4885HTR4 4666/4885DRD4 4797/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | SIGMAR1 3576/4885HTR4 4784/4885DRD4 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.